UpTick.com Pandemic Influenza Research Sector Alert -- Major Movements Reported
Mr Roger K. Olsson | 31.07.2007 18:50 | Analysis | Other Press | Technology | London | World
Tuesday, July 31, 2007
Jul. 31, 2007 (M2 Communications Ltd. delivered by Newstex) --
A 22-year-old Vietnamese woman tested positive for the H5N1 strain of the bird flu, Thanh Nien News reported Tuesday.
The newspaper said the woman was being treated for pneumonia at Hanoi's Bach Mai hospital when tests indicated she had the bird flu virus.
The Health Ministry said the woman, a farmer from the northern Ha Tay province, is in acute respiratory distress and is breathing with the help of a respirator, the report said.
Worldwide, the virus has killed at least 192 people, with millions of birds killed as precautions. To date, the people killed by the virus have mostly worked around poultry, but governments and scientists fear the H5N1 strain could mutate and pass more easily between birds and humans.
Companies such as Scottsdale, Arizona based ImmuneRegen Biosciences, Inc. (OTC Bulletin Board: IRBO) are focused on developing effective vaccines against the H5N1 strain, as well as other strains, in readiness for a possible pandemic.
IR BioSciences Holdings Inc., through its wholly owned subsidiary ImmuneRegen BioSciences, Inc., is a development stage biotechnology company focused on the research and development of Homspera(TM) and its derivatives Radilex(TM) and Viprovex(TM), which are under study as candidate therapeutic countermeasures for multiple homeland security bioterrorism threats. To view most recent full press release, go to: http://uptick.com/modules.php?name=Profiles&file=article&sid=3318.
UpTick.com's Pandemic Influenza Research sector consists of companies that research and develop treatments for Pandemic Flu.
Visit www.UpTick.com for more Small Cap News and Information.
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made on behalf of the company. All such forward-looking statements are, by necessity, only estimates of future results and actual results.
StoneRidge Capital, LLC is not a licensed broker, broker dealer, market marker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on www.uptick.com. StoneRidge Capital, LLC. and or its affiliates have received: $30000 USD and 100000 shares of restricted stock from IRBO. StoneRidge Capital, LLC's affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this profile and may profit in the event those shares rise in value. StoneRidge Capital, LLC does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
(Comments on this story may be sent to tww.feedback@m2.com)
Newstex ID: MCOM-0001-18550022
Delivered by Newstex LLC
via theFinancials.com
Mr Roger K. Olsson
e-mail:
rogerkolsson@yahoo.co.uk
Homepage:
http://www.adbrite.com/mb/commerce/purchase_form.php?opid=377909&afsid=1